CoChat
Sign Up
Cited by 127Mesenchymal stem cell researchCancer Cells and MetastasisSarcoma Diagnosis and Treatment

Mesenchymal stem cells in the osteosarcoma microenvironment: their biological properties, influence on tumor growth, and therapeutic implications

Open access
Zheng, Ying, Wang, Gangyang, Chen, Ruiling, Hua, Yingqi, Cai, Zhengdong·2018·Stem Cell Research & Therapy
DOI 10.1186/s13287-018-0780-xPMC PMC5793392
Open this paper in CoChat — free accountOpen PDF

Abstract

During tumorigenesis and development, participation of the tumor microenvironment is not negligible. As an important component in the tumor microenvironment, mesenchymal stem cells (MSCs) have been corroborated to mediate proliferation, metastasis, and drug resistance in many cancers, including osteosarcoma. What's more, because of tumor site tropism, MSCs can be engineered to be loaded with therapeutic agents so that drugs can be precisely delivered to tumor lesions. In this review, we mainly discuss recent advances concerning the functions of MSCs in osteosarcoma and their possible clinical applications in the future.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13287-018-0780-x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a mouse OS model, direct injections of MSCs into the OS tumor site exhibited a significant decrease in local recurrence and a hinderance of OS tumor cell growth compared to intravenous MSCs, MSCs at the surgical area, and no MSCs.

    “The mice receiving direct injections of MSCs into the OS tumor site exhibited a significant decrease in local recurrence and a hinderance of OS tumor cell growth compared to the other groups, suggesting that MSCs could be promising for enhancing bone healing in patients with lesions after surgery.”

    From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [102]

    In “Promoting bone reconstruction in OS patients” (page not provided), the review describes intravenous MSCs, MSCs at the surgical area, and no MSCs—not a direct tumor-site injection group. It reports no apparent difference in local recurrence or recurrent-tumor size among the three groups, contrary to the claimed significant reduction and inhibited growth. (LLM, conf=0.91)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

  • Low concentrations of injected ASCs into a tumor xenograft led to inhibition of OS tumor growth, while higher concentrations led to stimulation of tumor growth.

    “They found that low concentrations of injected ASCs into a tumor xenograft led to the inhibition of OS tumor growth, while higher concentrations of injected ASCs led to the stimulation of tumor growth [102,103,104,105].”

    From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [102]

    In “Promoting bone reconstruction in OS patients” (page unavailable), the review reports that ASCs can exacerbate osteosarcoma growth and cautions that the number of MSCs administered matters. It does not report a xenograft experiment in which low ASC concentrations inhibit growth while higher concentrations stimulate it. (LLM, conf=0.79)

    Experimental — accuracy not yet measured

  • MSCs could be promising for enhancing bone healing in patients with lesions after surgery.

    “The mice receiving direct injections of MSCs into the OS tumor site exhibited a significant decrease in local recurrence and a hinderance of OS tumor cell growth compared to the other groups, suggesting that MSCs could be promising for enhancing bone healing in patients with lesions after surgery.”

    From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [102]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 50

  1. [1]Wang M Zhao J Zhang L Wei F Lian Y Wu Y Gong Z Zhang S Zhou J Cao K Li X Xiong W Li G Zeng Z Guo C Role of tumor microenvironment in tumorigenesis J Cancer. 2017 8 761 73 10.7150/jca.17648 28382138 PMC5381164 · DOI · Paper page
  2. [2]Ye J Wu D Wu P Chen Z Huang J The cancer stem cell niche: cross talk between cancer stem cells and their microenvironment Tumor Biol. 2014 35 3945 51 10.1007/s13277-013-1561-x 24420150 · DOI
  3. [3]Hass R Kasper C Bohm S Jacobs R Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC Cell Commun Signal. 2011 9 12 10.1186/1478-811X-9-12 21569606 PMC3117820 · DOI
  4. [4]Viswanathan S Keating A Deans R Hematti P Prockop D Stroncek DF Stacey G Weiss DJ Mason C Rao MS Soliciting strategies for developing cell-based reference materials to advance mesenchymal stromal cell research and clinical translation Stem Cells Dev. 2014 23 1157 67 10.1089/scd.2013.0591 24422625 PMC4027980 · DOI
  5. [5]Dominici M Le Blanc K Mueller I Slaper-Cortenbach I Marini F Krause D Deans R Keating A Prockop D Horwitz E Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement Cytotherapy. 2006 8 315 7 10.1080/14653240600855905 16923606 · DOI · Paper page
  6. [6]De Francesco F Tirino V Desiderio V Ferraro G D'Andrea F Giuliano M Libondi G Pirozzi G De Rosa A Papaccio G Human CD34/CD90 ASCs are capable of growing as sphere clusters, producing high levels of VEGF and forming capillaries PLoS One. 2009 4 e6537 10.1371/journal.pone.0006537 19657392 PMC2717331 · DOI
  7. [7]Ferraro GA De Francesco F Nicoletti G Paino F Desiderio V Tirino V D'Andrea F Human adipose CD34+ CD90+ stem cells and collagen scaffold constructs grafted in vivo fabricate loose connective and adipose tissues J Cell Biochem. 2013 114 1039 49 10.1002/jcb.24443 23129214 · DOI
  8. [8]Sun Z Wang S Zhao RC The roles of mesenchymal stem cells in tumor inflammatory microenvironment J Hematol Oncol. 2014 7 14 10.1186/1756-8722-7-14 24502410 PMC3943443 · DOI · Paper page
  9. [9]Johann PD Vaegler M Gieseke F Mang P Armeanu-Ebinger S Kluba T Handgretinger R Muller I Tumour stromal cells derived from paediatric malignancies display MSC-like properties and impair NK cell cytotoxicity BMC Cancer. 2010 10 501 10.1186/1471-2407-10-501 20858262 PMC2949810 · DOI
  10. [10]De Wever O Van Bockstal M Mareel M Hendrix A Bracke M Carcinoma-associated fibroblasts provide operational flexibility in metastasis Semin Cancer Biol. 2014 25 33 46 10.1016/j.semcancer.2013.12.009 24406210 · DOI
  11. [11]Lourenco S Teixeira VH Kalber T Jose RJ Floto RA Janes SM Macrophage migration inhibitory factor-CXCR4 is the dominant chemotactic axis in human mesenchymal stem cell recruitment to tumors J Immunol 1950 194 2015 3463 74 PMC4374168 25712213
  12. [12]Wang JY, Wu PQ, Chen PC, Lee CW, Chen WM, Hung SC. Generation of osteosarcomas from a combination of Rb silencing and c-Myc overexpression in human mesenchymal stem cells. Stem Cells Transl Med. 2016;6:512–16. PMC5442803 28191765
  13. [13]Rubio R Gutierrez-Aranda I Saez-Castillo AI Labarga A Rosu-Myles M Gonzalez-Garcia S Toribio ML Menendez P Rodriguez R The differentiation stage of p53-Rb-deficient bone marrow mesenchymal stem cells imposes the phenotype of in vivo sarcoma development Oncogene. 2013 32 4970 80 10.1038/onc.2012.507 23222711 · DOI
  14. [14]Rubio R Abarrategi A Garcia-Castro J Martinez-Cruzado L Suarez C Tornin J Santos L Astudillo A Colmenero I Mulero F Rosu-Myles M Menendez P Rodriguez R Bone environment is essential for osteosarcoma development from transformed mesenchymal stem cells Stem Cells. 2014 32 1136 48 10.1002/stem.1647 24446210 · DOI
  15. [15]Shimizu T Ishikawa T Sugihara E Kuninaka S Miyamoto T Mabuchi Y Matsuzaki Y Tsunoda T Miya F Morioka H Nakayama R Kobayashi E Toyama Y Kawai A Ichikawa H Hasegawa T Okada S Ito T Ikeda Y Suda T Saya H c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis Oncogene 2010 29 5687 99 10.1038/onc.2010.312 20676132 · DOI
  16. [16]Riggi N Cironi L Provero P Suva ML Stehle JC Baumer K Guillou L Stamenkovic I Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma Cancer Res. 2006 66 7016 23 10.1158/0008-5472.CAN-05-3979 16849546 · DOI
  17. [17]Mohseny AB Szuhai K Romeo S Buddingh EP Briaire-de Bruijn I de Jong D van Pel M Cleton-Jansen AM Hogendoorn PC Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2 J Pathol. 2009 219 294 305 10.1002/path.2603 19718709 · DOI
  18. [18]Rodriguez R Rubio R Menendez P Modeling sarcomagenesis using multipotent mesenchymal stem cells Cell Res. 2012 22 62 77 10.1038/cr.2011.157 21931359 PMC3351912 · DOI
  19. [19]Arinzeh TL Tran T McAlary J Daculsi G A comparative study of biphasic calcium phosphate ceramics for human mesenchymal stem-cell-induced bone formation Biomaterials. 2005 26 3631 8 10.1016/j.biomaterials.2004.09.035 15621253 · DOI
  20. [20]Chang AI Schwertschkow AH Nolta JA Wu J Involvement of mesenchymal stem cells in cancer progression and metastases Curr Cancer Drug Targets. 2015 15 88 98 10.2174/1568009615666150126154151 25619387 · DOI
  21. [21]Mohseny AB Xiao W Carvalho R Spaink HP Hogendoorn PC Cleton-Jansen AM An osteosarcoma zebrafish model implicates Mmp-19 and Ets-1 as well as reduced host immune response in angiogenesis and migration J Pathol. 2012 227 245 53 10.1002/path.3998 22297719 · DOI
  22. [22]Soler A Angulo-Urarte A Graupera M PI3K at the crossroads of tumor angiogenesis signaling pathways Mol Cell Oncol. 2015 2 e975624 10.4161/23723556.2014.975624 27308431 PMC4905058 · DOI
  23. [23]Hung SC Pochampally RR Chen SC Hsu SC Prockop DJ Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis Stem Cells. 2007 25 2363 70 10.1634/stemcells.2006-0686 17540857 · DOI · Paper page
  24. [24]Cortini M Massa A Avnet S Bonuccelli G Baldini N Tumor-activated mesenchymal stromal cells promote osteosarcoma stemness and migratory potential via IL-6 secretion PLoS One. 2016 11 e0166500 10.1371/journal.pone.0166500 27851822 PMC5112800 · DOI
  25. [25]Zhang P Dong L Long H Yang TT Zhou Y Fan QY Ma BA Homologous mesenchymal stem cells promote the emergence and growth of pulmonary metastases of the rat osteosarcoma cell line UMR-106 Oncol Lett. 2014 8 127 32 10.3892/ol.2014.2127 24959232 PMC4063563 · DOI
  26. [26]Zhang P Dong L Yan K Long H Yang TT Dong MQ Zhou Y Fan QY Ma BA CXCR4-mediated osteosarcoma growth and pulmonary metastasis is promoted by mesenchymal stem cells through VEGF Oncol Rep. 2013 30 1753 61 10.3892/or.2013.2619 23863999 · DOI · Paper page
  27. [27]Baglio SR, Lagerweij T, Perez Lanzon M, Xuan Ho D, Leveille N, Melo SA, Cleton-Jansen AM, Jordanova ES, Roncuzzi L, Greco M, van Eijndhoven MA, Grisendi G, Dominici M, Bonafede R, Lougheed S, de Gruijl TD, Zini N, Cervo S, Steffan A, Canzonieri V, Martson A, Maasalu K, Koks S, Wurdinger T, Baldini N, Pegtel DM, Blocking tumor-educated MSC paracrine activity halts osteosarcoma progression. Clin Cancer Res. 2017;23:3721–33. 28053020
  28. [28]Tu B Peng ZX Fan QM Du L Yan W Tang TT Osteosarcoma cells promote the production of pro-tumor cytokines in mesenchymal stem cells by inhibiting their osteogenic differentiation through the TGF-beta/Smad2/3 pathway Exp Cell Res. 2014 320 164 73 10.1016/j.yexcr.2013.10.013 24183998 · DOI
  29. [29]Macklin R Wang H Loo D Martin S Cumming A Cai N Lane R Ponce NS Topkas E Inder K Saunders NA Endo-Munoz L Extracellular vesicles secreted by highly metastatic clonal variants of osteosarcoma preferentially localize to the lungs and induce metastatic behaviour in poorly metastatic clones Oncotarget. 2016 7 43570 87 10.18632/oncotarget.9781 27259278 PMC5190045 · DOI
  30. [31]Gao T Li JZ Lu Y Zhang CY Li Q Mao J Li LH The mechanism between epithelial mesenchymal transition in breast cancer and hypoxia microenvironment Biomed Pharmacother. 2016 80 393 405 10.1016/j.biopha.2016.02.044 27133080 · DOI
  31. [33]Avnet S Di Pompo G Chano T Errani C Ibrahim-Hashim A Gillies RJ Donati DM Baldini N Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-kappaB activation Int J Cancer. 2017 140 1331 45 10.1002/ijc.30540 27888521 PMC5272857 · DOI
  32. [34]Papaccio F Paino F Regad T Papaccio G Desiderio V Tirino V Cancer cells, cancer stem cells, and mesenchymal stem cells: influence in cancer development Stem Cells Transl Med. 2017 6 2115 25 10.1002/sctm.17-0138 29072369 PMC5702541 · DOI
  33. [35]Gibbs CP Kukekov VG Reith JD Tchigrinova O Suslov ON Scott EW Ghivizzani SC Ignatova TN Steindler DA Stem-like cells in bone sarcomas: implications for tumorigenesis Neoplasia. 2005 7 967 76 10.1593/neo.05394 16331882 PMC1502023 · DOI
  34. [36]Tirino V Desiderio V Paino F De Rosa A Papaccio F Fazioli F Pirozzi G Papaccio G Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo FASEB J. 2011 25 2022 30 10.1096/fj.10-179036 21385990 · DOI
  35. [37]Tome Y Tsuchiya H Hayashi K Yamauchi K Sugimoto N Kanaya F Tomita K Hoffman RM In vivo gene transfer between interacting human osteosarcoma cell lines is associated with acquisition of enhanced metastatic potential J Cell Biochem. 2009 108 362 7 10.1002/jcb.22259 19623575 · DOI
  36. [38]Abdullah LN Chow EK Mechanisms of chemoresistance in cancer stem cells Clin Transl Med. 2013 2 3 10.1186/2001-1326-2-3 23369605 PMC3565873 · DOI
  37. [39]Lis R Touboul C Mirshahi P Ali F Mathew S Nolan DJ Maleki M Abdalla SA Raynaud CM Querleu D Al-Azwani E Malek J Mirshahi M Rafii A Tumor associated mesenchymal stem cells protects ovarian cancer cells from hyperthermia through CXCL12 Int J Cancer. 2011 128 715 25 10.1002/ijc.25619 20725999 · DOI
  38. [41]Gauthaman K Yee FC Cheyyatraivendran S Biswas A Choolani M Bongso A Human umbilical cord Wharton's jelly stem cell (hWJSC) extracts inhibit cancer cell growth in vitro J Cell Biochem. 2012 113 2027 39 10.1002/jcb.24073 22275115 · DOI
  39. [44]Duchi S Sotgiu G Lucarelli E Ballestri M Dozza B Santi S Guerrini A Dambruoso P Giannini S Donati D Ferroni C Varchi G Mesenchymal stem cells as delivery vehicle of porphyrin loaded nanoparticles: effective photoinduced in vitro killing of osteosarcoma J Control Release. 2013 168 225 37 10.1016/j.jconrel.2013.03.012 23524189 · DOI
  40. [45]Shah K Mesenchymal stem cells engineered for cancer therapy Adv Drug Deliv Rev. 2012 64 739 48 10.1016/j.addr.2011.06.010 21740940 PMC3395998 · DOI
  41. [46]Zhao Y Tang S Guo J Alahdal M Cao S Yang Z Zhang F Shen Y Sun M Mo R Zong L Jin L Targeted delivery of doxorubicin by nano-loaded mesenchymal stem cells for lung melanoma metastases therapy Sci Rep. 2017 7 44758 10.1038/srep44758 28303966 PMC5355993 · DOI
  42. [47]Niess H von Einem JC Thomas MN Michl M Angele MK Huss R Gunther C Nelson PJ Bruns CJ Heinemann V Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial BMC Cancer. 2015 15 237 10.1186/s12885-015-1241-x 25879229 PMC4393860 · DOI
  43. [48]Subbiah V Wagner MJ McGuire MF Sarwari NM Devarajan E Lewis VO Westin S Kato S Brown RE Anderson P Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine Oncotarget. 2015 6 40642 54 26510912 PMC4747358
  44. [50]Ling W Zhang J Yuan Z Ren G Zhang L Chen X Rabson AB Roberts AI Wang Y Shi Y Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment Cancer Res. 2014 74 1576 87 10.1158/0008-5472.CAN-13-1656 24452999 PMC3959857 · DOI
  45. [51]Kinnaird T Stabile E Burnett MS Lee CW Barr S Fuchs S Epstein SE Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms Circ Res. 2004 94 678 85 10.1161/01.RES.0000118601.37875.AC 14739163 · DOI · Paper page
  46. [52]Liu A Xue GH Sun M Shao HF Ma CY Gao Q Gou ZR Yan SG Liu YM He Y 3D printing surgical implants at the clinic: a experimental study on anterior cruciate ligament reconstruction Sci Rep. 2016 6 21704 10.1038/srep21704 26875826 PMC4753687 · DOI
  47. [53]Aanstoos ME Regan DP Rose RJ Chubb LS Ehrhart NP Do mesenchymal stromal cells influence microscopic residual or metastatic osteosarcoma in a murine model? Clin Orthop Relat Res. 2016 474 707 15 10.1007/s11999-015-4362-2 26018200 PMC4746149 · DOI · Paper page
  48. [54]Perrot P Rousseau J Bouffaut AL Redini F Cassagnau E Deschaseaux F Heymann MF Heymann D Duteille F Trichet V Gouin F Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence PLoS One. 2010 5 e10999 10.1371/journal.pone.0010999 20544017 PMC2882323 · DOI · Paper page
  49. [55]Paino F La Noce M Di Nucci D Nicoletti GF Salzillo R De Rosa A Ferraro GA Papaccio G Desiderio V Tirino V Human adipose stem cell differentiation is highly affected by cancer cells both in vitro and in vivo: implication for autologous fat grafting Cell Death Dis. 2017 8 e2568 10.1038/cddis.2016.308 28102844 PMC5386348 · DOI
  50. [56]Fink DW Jr FDA regulation of stem cell-based products Science. 2009 324 1662 3 10.1126/science.1173712 19556496 · DOI

Cited by

Sorted by citations

Authors
Zheng, Y., Wang, G., Chen, R., Hua, Y., & Cai, Z.
Affiliations
Shanghai Jiao Tong University (CN)
Corresponding author
  • Wang, Gangyang
  • Hua, Yingqi
  • Cai, Zhengdong
ORCID
Venue
Stem Cell Research & Therapy
Publisher
Springer Science and Business Media LLC
Published
2018-01-31
Volume
9
Issue
1
Pages
22-22
ISSN
1757-6512 (ISSN-L)
DOI
10.1186/s13287-018-0780-x
PMC
PMC5793392
OpenAlex
W2797890752
Cited by
127
References
6
Citations by year
2026: 10 · 2025: 13 · 2024: 13 · 2023: 19 · 2022: 12 · 2021: 19 · 2020: 23 · 2019: 11 · 2018: 7
FWCI
2.15
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Stem Cell Research & Therapy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
National Natural Science Foundation of China (81202115)
Topics
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
Keywords
mesenchymal stem cells, osteosarcoma, tumor microenvironment, tumor growth, metastasis, drug resistance, tumor tropism, targeted drug delivery, cancer therapy
MeSH terms
Animals, Bone Neoplasms, Humans, Neoplasm Metastasis, Osteosarcoma, Drug Resistance, Neoplasm, Cell Proliferation, Tumor Microenvironment, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review